Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India

Annals of Oncology

Volumn 24, Issue SUPPLEMENT5, 2013, Pages

  Lopes, G L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; GEMCITABINE; GEMITA; GENERIC DRUG; IRINOTECAN; OXALIPLATIN; OXITAN; PACLITAXEL; UNCLASSIFIED DRUG; CAMPTOTHECIN; DEOXYCYTIDINE; PLATINUM COMPLEX; TAXOID;

ARTICLE; BREAST CANCER; CANCER CONTROL; COLORECTAL CANCER; COST CONTROL; DRUG COST; HEALTH CARE ACCESS; HEALTH ECONOMICS; HUMAN; INDIA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; ECONOMICS; NEOPLASMS; POVERTY;

CAMPTOTHECIN; COST SAVINGS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DRUGS, GENERIC; HUMANS; INDIA; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; POVERTY; TAXOIDS;

EID: 84883020996     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt323     Document Type: Article

References (20)

1. World health organization. United Nations High Level Meeting on Noncommunicable Disease Prevention and Control. http://www.who.int/nmh/events/un_ncd_summit2011/en/ (20 August 2012, date last accessed).
2. General Assembly. Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. Resolution 66/2. United Nations, 2011. http://www.who.int/nmh/events/un_ncd_summit2011/political_declaration_en.pdf (20 August 2012, date last accessed).
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11): e442.
4. LiveStrong foundation and American Cancer Society. The Global Economic Cost of Cancer. http://www.cancer.org/acs/groups/content/internationalaffairs/documents/document/acspc-026203.pdf (20 August 2012, date last accessed).
5. National Cancer Institute. A Snapshot of Pediatric Cancers. Incidence and Mortality Rate Trends. http://www.cancer.gov/researchandfunding/snapshots/pdf/Pediatric-Snapshot.pdf. (20 August 2012, date last accessed).
6. Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One 2010; 5(3): e9584.
7. Altekruse SF, Kosary CL, Krapcho M et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010. (20 August 2012, date last accessed).
8. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2012; 9(3): 1474-1776.
9. United States Food and Drug Administration. Understanding Generic Drugs. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/default.htm (10 October 2012, date last accessed).
10. Generic pharmaceutical association. About Generics. http://www.gphaonline.org/about-gpha/about-generics (10 October 2012, date last accessed).
11. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
12. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
13. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Eng J Med 2011; 364(19): 1817-1825.
14. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377(9769): 914-923.
15. International Agency for Research on Cancer. GLOBOCAN, India 2008. http://globocan.iarc.fr/factsheet.asp (12 December 2012, date last accessed).
16. The world bank. Health Expenditures Per Capita (current USD). http://data.worldbank.org/indicator/SH.XPD.PCAP (31 August 2012, date last accessed).
17. The world bank. Data: India. http://data.worldbank.org/country/india (31 August 2012, date last accessed).
18. Shrank WH, Liberman JN, Fischer MA et al. Physician perceptions about generic drugs. Ann Pharmacother 2011; 45: 31-38.
19. Alwan F, Alshami A, Hatim A et al. Impact of switching therapy from imatinib mesylate to generic copy of Imatinib on hematologic response in patients with chronic phase chronic myeloid leukemia: single center study. Hematologica 2011; 96(2): Abstract 1219.
20. Kesselheim AS, Misono AS, Lee JL et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and metaanalysis. JAMA 2008; 300(21): 2514-2526.